Your search history is turned on.
Date: January 2, 2019 Jurisdictions: Alberta, British Columbia
Microsoft Word - 181031pharmalogixInvCFOFV2_cwm.doc 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Lucas Birdsall, Chief Financial Officer of Pharmalogix Investments Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) o...
Microsoft Word - 181031pharmalogixInvCEOFV2_cwm.doc 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Lucas Birdsall, Chief Executive Officer of Pharmalogix Investments Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Pharm...
Microsoft Word - 180731pharmalogixInvMDA_cwm.docx PHARMALOGIX INVESTMENTS CORP. MANAGEMENTS DISCUSSION AND ANALYSIS FOR THE THREE MONTHS AND SIX MONTHS ENDED OCTOBER 31, 2018 (All amounts expressed in Canadian dollars, unless otherwise stated) This managements discussion and analysis (MD&A) of the operating results and financial position of Pharmal...
Microsoft Word - Viena_Q3_FS_2018.docx Pharmalogix Investments Corp. (formerly Viena Capital Corp.) Unaudited Condensed Interim Financial Statements For the Six Months Ended October 31, 2018 (Expressed in Canadian dollars) NOTICE OF NO AUDITOR REVIEW OF ...
Date: December 21, 2018 Jurisdictions: Alberta, British Columbia
Pharmalogix - MVSA loan material change report (W0370748).DOCX {W0370748} FORM 51-102F3 Material Change Report ITEM 1. Name and Address of Company Pharmalogix Investments Corp. (the Company or Pharmalogix) Suite 335 1917 West 4th Ave., Vancouver, British Columbia, V6J 1M7 ITEM 2. Date of Material Change ...
Date: October 1, 2018 Jurisdictions: Alberta, British Columbia
Microsoft Word - 180731pharmalogixInvCFOFV2_cwm.doc 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Lucas Birdsall, Chief Financial Officer of Pharmalogix Investments Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings...
Microsoft Word - 180731pharmalogixInvCEOFV2_cwm.doc 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Lucas Birdsall, Chief Executive Officer of Pharmalogix Investments Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Pha...
Microsoft Word - 180731pharmalogixInvMDA_cwm.docx PHARMALOGIX INVESTMENTS CORP. MANAGEMENTS DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2018 (All amounts expressed in Canadian dollars, unless otherwise stated) This managements discussion and analysis (MD&A) of the operating results and financial position of Pharmalogix Investments Corp. and ...